Skip to main content

Knight Therapeutics Inc(GUD-T)
TSX

Today's Change
Real-Time Last Update

Stocks in play: Knight Therapeutics Inc.,

Baystreet - Thu Feb 29, 8:55AM CST

Announced today the launch of Minjuvi® (tafasitamab) by its Brazilian affiliate, United Medical Ltda. Minjuvi® is indicated in combination with lenalidomide, followed by Minjuvi® monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant. Knight Therapeutics Inc., shares T.GUD are trading down $0.14 at $5.41.

Provided Content: Content provided by Baystreet. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe